RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Once finalized, cough syrups will no longer be available for over-the-counter sale
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Subscribe To Our Newsletter & Stay Updated